UK: GSK Awarded Arrow Declaration In Patent Dispute With Vectura

GlaxoSmithKline ("GSK") has succeeded in the High Court of England and Wales in its patent dispute with Vectura, a UK based pharmaceutical company specialising in formulation of inhalable medicaments. GSK was successful in both its Gillette defence and in obtaining the award of an Arrow declaration.

The judgment of Mr Justice Arnold in Glaxo Group Limited & Ors v Vectura [2018] EWHC 3414 (Pat) (13 December 2018) is notable for two key reasons:

  1. GSK's success in a case primarily based on a "Gillette defence": that GSK's own manufacturing processes and the resulting products would have been obvious to the skilled person at the priority date of the patent in suit. This was despite the judge declining to find that Vectura's patents in suit were obvious (although he did find them invalid for insufficiency by way of ambiguity);
  2. Arnold J's conclusion that on the "unusual" facts of this case, the award of an Arrow declaration would serve a useful purpose: it would formalise and emphasise that GSK's own manufacturing processes (and their direct products) were obvious. In the context of Vectura's further pending patent applications covering the use of key excipient ingredients, the Arrow declaration would avoid the judge's conclusions on the Gillette defence being interpreted as obiter.

GSK's successful Gillette defence

GSK's success on its Gillette defence (see Gillette v Anglo-American Trading [1913] 30 RPC 465) was specific to the facts of the case: in addition to the Judge finding that GSK's processes (for formulating its proprietary active ingredient) were obvious over the pleaded prior art, he also found that it was not possible to determine when the patented invention had been performed (i.e. whether 'magnesium stearate' had been structurally combined with, and "fused" to, particles of active ingredient). This meant that (i) each of Vectura's five patents in issue was insufficient for ambiguity and (ii) infringement of them had not been established.

GSK's success in securing the award of an Arrow declaration

The judge's reasoning underpinning his award of an Arrow declaration (see Arrow Generics v Merck [2007] EWHC 1900 (Pat) and Fujifilm v AbbVie [2017] EWHC 395 (Pat)) provides valuable further guidance on the conditions needed to be satisfied for an award of this relatively new form of relief, as well as on the types of factual situation in which those conditions may be satisfied.

Vectura's patents in suit were a subset of a wider group of patents defined by a previous agreement between GSK and Vectura as "Non-Assert Patents". In the course of Vectura's earlier unsuccessful attempt to strike out GSK's claim for Arrow relief, Vectura had given an undertaking not to sue GSK under any of the Non-Assert Patents. ( Our commentary on the interim dispute regarding strike out is available here).

In the meantime, GSK had identified another pending application of Vectura's, "415", which was outside of the Non-Assert Patents, but which related to the same technical subject matter of the Non-Assert Patents, or at least had the potential for further divisional patents to be filed covering that technical subject matter. Vectura, however, declined to extend its undertaking beyond the Non-Assert Patents to cover 415 also.

Following the Court of Appeal's judgment in Fujifilm v AbbVie [2017] EWCA 1, it has been clear that for an Arrow declaration to be granted, there must be more than just a finding that the relevant subject matter is obvious (in this case the finding made as part of GSK's Gillette defence). As Arnold J put it in this GSK v Vectura judgment, "that is a necessary, but not sufficient, foundation for the relief": there must also be a "useful purpose" in granting the declaration.

In late 2017, in Generics v Yeda [2017] EWHC 2629 (Pat), Arnold J declined to grant an Arrow declaration for want of a useful purpose over the finding he had already made: that Generics' product in a particular dosing regimen was obvious at a particular date. In GSK v Vectura, however, Arnold J distinguished his judgment in Generics v Yeda in three ways:

"254. ... First, Vectura have failed to establish infringement of the Patents because they have not been able to identify a suitable analytical technique to demonstrate that certain requirements of the claims of the Patents are satisfied. Vectura would not necessarily face the same difficulty with differently formulated claims."

"255. Secondly, I have not found that the Patents were obvious. It would be an open question as to whether patents with differently formulated claims were obvious or not."

"256. Thirdly, and most significantly, Vectura has given an undertaking which is designed to give GSK comfort that, if they are successful in defeating Vectura's claims for infringement of the Patents, then they will not be vexed by further claims for infringement of other patents by the same process and products; yet Vectura's undertaking does not extend to patents deriving from (for example) 415. Counsel for Vectura was unable to give me any explanation for Vectura's unwillingness to extend its undertaking to (at least) 415. It follows that GSK are potentially at risk of a claim for infringement of a patent deriving from (at least) 415."

It is the third reason, the most significant for Arnold J, which carries a warning for legal professionals. Offering undertakings during proceedings can be seen as a way to cut down the scope of dispute, and indeed in the case of a claim for an Arrow declaration may be a way to curtail such a claim before it gets off the ground, by stripping it of useful purpose.

However, in order to achieve this, an undertaking must go far enough to remove all useful purpose. If a party caveats or limits the scope of its undertaking, it must be ready to explain comprehensively why that is appropriate. Without such a comprehensive explanation, any partial undertaking is more likely simply to highlight to the court that there is, indeed, a useful purpose in the relief sought.

This case marks the second Arrow declaration to be granted, the first being Fujifilm v AbbVie [2017] EWHC 395 (Pat), in relation to which Gowling WLG also acted for the successful party.

A copy of the judgment can be found here Glaxo Group Ltd & Ors v Vectura Ltd [2018] EWHC 3414 (Pat).

Read the original article on

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions